NANJING PROBIO BIOTECH CO LTD

Overview

NANJING PROBIO BIOTECH CO LTD is an active pharmaceutical ingredient (API) supplier with 17 active FDA Type II Drug Master Files, covering ARG34GLP-1(9-37)(H1); BSAL; BSPQI; DNASE I; HOST CELL LINES CHOK1-GENS AND CHOKI-ADCC+, VECTORS; MRNA CAP 2'-O-METHYLTRANSFERASE.

API / Drug Master Files

NANJING PROBIO BIOTECH CO LTD holds 17 active (17 total) FDA Type II Drug Master Files — identifying it as an active-substance / API supplier. Type II DMFs are filed with the FDA to support the use of an active pharmaceutical ingredient in drug applications.

• UPROCHO™ FB MEDIUM COMBINATIONActive2025-09-25
• ARG34GLP-1(9-37)(H1)Active2024-12-05
• XBAIActive2024-12-02
• MRNA CAP 2'-O-METHYLTRANSFERASEActive2024-10-30
• UPROCHO™ FB MEDIUM SYSTEMActive2024-10-04
• RECOMBINANT CPB (LYOPHILIZED POWDER)Active2024-09-29
• VACCINIA CAPPING ENZYMEActive2024-08-30
• BSALActive2024-07-31
• BSPQIActive2024-05-30
• T7 TURBO RNA POLYMERASEActive2024-04-29
• DNASE IActive2024-03-14
• MURINE RNASE INHIBITORActive2023-12-27
• PYROPHOSPHATASE, INORGANIC (YEAST)Active2023-10-25
• T7 RNA POLYMERASEActive2023-08-22
• MURINE RNASE INHIBITOR NEOActive2023-07-19

Showing 15 of 17 Drug Master Files.

FDA compliance signals

No FDA recalls, Warning Letters, or Form 483 observations are linked to NANJING PROBIO BIOTECH CO LTD in our records. PharmaTek screens the full directory against live FDA enforcement data.